Kurs
-4,45%
Kalender
Est. tid* | ||
2026-02-20 | 08:30 | Bokslutskommuniké 2025 |
2025-11-14 | 08:30 | Kvartalsrapport 2025-Q3 |
2025-08-22 | 08:30 | Kvartalsrapport 2025-Q2 |
2025-06-05 | - | X-dag ordinarie utdelning PERP B 0.00 SEK |
2025-06-04 | - | Årsstämma |
2025-05-16 | - | Kvartalsrapport 2025-Q1 |
2025-02-14 | - | Bokslutskommuniké 2024 |
2024-11-22 | - | Kvartalsrapport 2024-Q3 |
2024-09-26 | - | Split PERP B 24:1 |
2024-08-30 | - | Extra Bolagsstämma 2024 |
2024-08-23 | - | Kvartalsrapport 2024-Q2 |
2024-06-17 | - | X-dag ordinarie utdelning PERP B 0.00 SEK |
2024-06-14 | - | Årsstämma |
2024-05-17 | - | Kvartalsrapport 2024-Q1 |
2024-02-16 | - | Bokslutskommuniké 2023 |
2023-11-17 | - | Kvartalsrapport 2023-Q3 |
2023-11-15 | - | Extra Bolagsstämma 2023 |
2023-08-25 | - | Kvartalsrapport 2023-Q2 |
2023-06-20 | - | Årsstämma |
2023-05-17 | - | Kvartalsrapport 2023-Q1 |
2023-05-05 | - | X-dag ordinarie utdelning PERP B 0.00 SEK |
2023-02-17 | - | Bokslutskommuniké 2022 |
2022-11-18 | - | Kvartalsrapport 2022-Q3 |
2022-08-25 | - | Kvartalsrapport 2022-Q2 |
2022-05-24 | - | Årsstämma |
2022-05-20 | - | Kvartalsrapport 2022-Q1 |
2022-05-09 | - | X-dag ordinarie utdelning PERP B 0.00 SEK |
2022-02-25 | - | Bokslutskommuniké 2021 |
2021-11-19 | - | Kvartalsrapport 2021-Q3 |
2021-08-27 | - | Kvartalsrapport 2021-Q2 |
2021-05-25 | - | Kvartalsrapport 2021-Q1 |
2021-05-04 | - | X-dag ordinarie utdelning PERP B 0.00 SEK |
2021-03-23 | - | Extra Bolagsstämma 2021 |
2021-02-12 | - | Bokslutskommuniké 2020 |
2020-11-24 | - | Kvartalsrapport 2020-Q3 |
2020-08-28 | - | Kvartalsrapport 2020-Q2 |
2020-06-16 | - | Extra Bolagsstämma 2020 |
2020-05-13 | - | X-dag ordinarie utdelning PERP B 0.00 SEK |
2020-04-23 | - | Kvartalsrapport 2020-Q1 |
2020-02-13 | - | Bokslutskommuniké 2019 |
2019-11-21 | - | Kvartalsrapport 2019-Q3 |
2019-08-29 | - | Kvartalsrapport 2019-Q2 |
2019-04-30 | - | X-dag ordinarie utdelning PERP B 0.00 SEK |
2019-04-29 | - | Årsstämma |
2019-04-26 | - | Kvartalsrapport 2019-Q1 |
2019-02-14 | - | Bokslutskommuniké 2018 |
2018-11-21 | - | Kvartalsrapport 2018-Q3 |
2018-08-29 | - | Kvartalsrapport 2018-Q2 |
2018-05-04 | - | Split PERP B 2:1 |
2018-05-03 | - | Kvartalsrapport 2018-Q1 |
2018-04-25 | - | Extra Bolagsstämma 2018 |
2018-03-16 | - | X-dag ordinarie utdelning PERP B 0.00 SEK |
2018-03-15 | - | Årsstämma |
2018-02-14 | - | Bokslutskommuniké 2017 |
2017-11-15 | - | Kvartalsrapport 2017-Q3 |
2017-08-29 | - | Kvartalsrapport 2017-Q2 |
2017-05-04 | - | X-dag ordinarie utdelning PERP B 0.00 SEK |
2017-05-03 | - | Årsstämma |
2017-05-03 | - | Kvartalsrapport 2017-Q1 |
2017-02-16 | - | Bokslutskommuniké 2016 |
2017-01-11 | - | Extra Bolagsstämma 2017 |
2016-11-25 | - | Kvartalsrapport 2016-Q3 |
2016-08-24 | - | Kvartalsrapport 2016-Q2 |
2016-04-25 | - | Årsstämma |
2016-04-25 | - | Kvartalsrapport 2016-Q1 |
2016-02-17 | - | Bokslutskommuniké 2015 |
2015-11-19 | - | Kvartalsrapport 2015-Q3 |
2015-08-26 | - | Kvartalsrapport 2015-Q2 |
2015-05-21 | - | Kvartalsrapport 2015-Q1 |
2015-03-26 | - | Årsstämma |
2015-03-05 | - | Bokslutskommuniké 2014 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Pharmacolog i Uppsala AB (publ) announces that the Board of Directors has decided to immediately dismiss Per Persson from his role as CEO. At the same time, the company's Chairman of the Board Erik Hedlund was appointed acting CEO of Pharmacolog.
The board has taken the decision based on its assessment that Per Persson is not the right person to lead the company. Erik Hedlund, with extensive experience in Pharmacolog, has now taken on the task of working with the way forward until a new CEO has been recruited. At the same time, the Board will complete the ongoing work with the company's strategic planning.
Erik Hedlund is a very experienced leader in MedTech with experience from both operational management and board work in many companies, such as Siemens Medical, RaySearch Laboratories AB and C-Rad AB.
The recruitment process of a new permanent CEO has begun now.
As a result of Erik Hedlund being appointed acting CEO, the Board has appointed Board member Björn Varnestig as the new Chairman of the Board. Erik Hedlund remains on the Board as an ordinary member.
This disclosure contains information that Pharmacolog is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 30-03-2023 07:18 CET.
Björn Varnestig, incoming Chairman of the Board
Email: bjorn@varnestig.se
Phone: +46 70-838 04 59
Erik Hedlund, incoming CEO
Email: erik.hedlund@nolsterbyinvest.se
Phone: +46 70-382 08 41